Xencor (XNCR) Other financing activities (2013 - 2024)
Xencor (XNCR) reported Other financing activities of -$12.1 million for Q4 2024, down 2515.4% year-over-year from $500000.0 in Q1 2024, and down 2515.4% quarter-over-quarter from $500000.0 in Q4 2023.
Xencor (XNCR) Other financing activities (2013 - 2024) Analysis & Trends
Xencor (XNCR) has 11 years of Other financing activities data on file, last reported at -$12.1 million in Q4 2024.
- Other financing activities for Q4 2024 came in at -$12.1 million, down 2515.4% year-over-year; the trailing twelve-month figure through Dec 2025 was -$14.9 million (down 9.45% YoY), and the FY2023 annual result was $500000.0, changed N/A from the prior year.
- Other financing activities retreated to -$12.1 million in Q4 2024 per XNCR's latest filing, from $500000.0 in the prior quarter.
- Over five years, Other financing activities peaked at $8.9 million in Q4 2020 and troughed at -$12.1 million in Q4 2024.
- A 5-year average of $360000.0 and a median of $1.3 million in 2022 frame the typical range for Other financing activities.
- The sharpest annual moves came in 2020 and 2024: Other financing activities jumped 283.97% in 2020, then plunged 2515.4% in 2024.
- A 5-year view of Other financing activities shows it stood at $8.9 million in 2020, then sank by 206.6% to -$9.5 million in 2021, then surged by 64.8% to -$3.3 million in 2022, then surged by 115.0% to $500000.0 in 2023, then sank by 2515.4% to -$12.1 million in 2024.
- Business Quant data shows XNCR's Other financing activities at -$12.1 million in Q4 2024, $500000.0 in Q4 2023, and -$3.3 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Xencor | 953.38 Mn | 878.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -12.08 Mn |
| Dec 31, 2024 | -12.08 Mn |
| Dec 31, 2023 | 500,000.00 |
| Dec 31, 2023 | 500,000.00 |
| Dec 31, 2022 | -3.33 Mn |
| Dec 31, 2022 | -3.33 Mn |
| Sep 30, 2022 | 1.29 Mn |
| Sep 30, 2022 | 1.29 Mn |
| Jun 30, 2022 | 1.32 Mn |
| Jun 30, 2022 | 1.32 Mn |
| Mar 31, 2022 | 731,000.00 |
| Mar 31, 2022 | 731,000.00 |
| Dec 31, 2021 | -9.47 Mn |
| Dec 31, 2021 | -9.47 Mn |
| Sep 30, 2021 | 3.23 Mn |
| Sep 30, 2021 | 3.23 Mn |
| Jun 30, 2021 | 903,000.00 |
| Jun 30, 2021 | 903,000.00 |
| Mar 31, 2021 | 5.34 Mn |
| Mar 31, 2021 | 5.34 Mn |